Docket No.: 100391-02030 Customer No.: 35745

REMARKS

Claims 1-45 were pending in this application and were subject to Restriction

Requirements. Claims 1, 7, 8, 11, 27, 33, 42 and 45 were amended and claims 4, 5, 30 and 31 were

canceled. Thus claims 1-3, 6-29 and 32-45 are still pending in the present application. Claims 1, 7, 8,

11, 27, 33, 42 and 45 were amended to better define the invention by replacing the term "catalyst" with

the term "catalytic antibody". Applicants maintain that the amendments do not introduce any new

matter. Specifically, support for the term "catalytic antibody" may be found in the specification on

page 1, lines 20 and 21.

Restriction Requirement and Election of Specie

Applicants elect claims 1-16 and 27-33, Group I, with traverse, for further prosecution in this

application. Applicants also elect the specie of "introducing a chemical moiety to said target

molecule" that "appears in claim 6.

Applicants respectfully traverse the Restriction Requirement for the same reasons indicated in

their Response of October 7, 2004.

Favorable reconsideration is earnestly solicited.

Dated: February 28, 2005

Respectfully submitted,

Charles C. Achkar

Reg. No.43,311

KRAMER LEVIN NAFTALIS & FRANKEL LLP

919 Third Avenue

New York, New York 10022

Tel.: (212) 715-9100

Fax.: (212) 715-8000